Cartesian Therapeutics reported approximately $947000 in revenue in Q4 2025, derived primarily from grant funding and collaboration revenue. The company posted an estimated net loss of about $36098000 for the quarter with EPS of -1.39, reflecting continued investment in clinical development including the Phase 3 AURORA trial.

Cartesian Therapeutics generated $452000 in revenue in Q3 2025, primarily from grant funding, while reporting a net loss of $35902000 as research and development spending increased to support ongoing clinical trials including the Phase 3 AURORA study of Descartes-08.

Cartesian Therapeutics reported $298000 in revenue in Q2 2025, a significant decline from the prior year due to the absence of collaboration milestone payments. Despite the drop in revenue and an operating loss, the company recorded net income of $15900000, primarily driven by changes in the fair value of contingent value right liabilities. The company ended the quarter with $162100000 in cash, cash equivalents and restricted cash to support clinical programs including the Phase 3 AURORA trial.

Cartesian Therapeutics generated $1047000 in revenue in Q1 2025 from collaboration and grant funding while reporting a net loss of $17700000 as the company continued investing in the clinical development of Descartes-08 and other autoimmune programs.

Cartesian Therapeutics reported a net loss of $(77.4) million for the full year ended December 31, 2024, with total revenue of $38.913 million. The company ended the year with approximately $214.3 million in cash, cash equivalents, and restricted cash, which is expected to support operations into mid-2027.

Cartesian Therapeutics reported cash, cash equivalents, and restricted cash of approximately $104.8 million as of March 31, 2024. Net loss was $(56.8) million, or $(10.50) per share.

Cartesian Therapeutics reported its full year 2023 financial results, highlighting a pro forma cash balance of $118.3 million as of December 31, 2023, expected to fund operations into the second half of 2026. The company is advancing its pipeline with key milestones anticipated, including topline data from the Phase 2b study of Descartes-08 in myasthenia gravis expected mid-2024 and initiation of a Phase 2 study of Descartes-08 in systemic lupus erythematosus in 1H24.